The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I

  • Exp Dermatol. 2018 Feb;27(2):201-204. doi: 10.1111/exd.13454.
Xiu-Qiong Fu  1 ,  Ji-Yao Chou  1 ,  Ting Li  1 ,  Pei-Li Zhu  1 ,  Jun-Kui Li  1 ,  Cheng-Le Yin  1 ,  Tao Su  1 ,  Hui Guo  1 ,  Kin-Wah Lee  1 ,  Muhammad Jahangir Hossen  1 ,  Gui-Xin Chou  2 ,  Zhi-Ling Yu  1  3
Affiliations
  • 1. Center for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
  • 2. Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • 3. Research and Development Centre for Natural Health Products, HKBU Shenzhen Research Institute and Continuing Education, Shenzhen, China.
PMID: 29078004 DOI: 10.1111/exd.13454
Abstract

In this study, we aimed to investigate the anti-melanoma effects and the JAK2/STAT3 pathway-related mechanism of action of atractylenolide I in human Melanoma cells. Our results showed that atractylenolide I effectively reduced viability, induced Apoptosis and inhibited migration of Melanoma cells. Meanwhile, atractylenolide I decreased the protein expression levels of phospho-JAK2 and phospho-STAT3, and in turn downregulated the mRNA levels of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9. Furthermore, the cytotoxic effect of atractylenolide I was attenuated in STAT3-overactivated A375 cells. These findings indicate that inhibition of JAK2/STAT3 signalling contributes to the anti-melanoma effects of atractylenolide I.

Keywords
Cytotoxicity; apoptosis; metastasis; molecular pathways; targeted therapy.
Products